Fas Signaling pp 128-144 | Cite as

The FasL-Fas System in Disease and Therapy

  • Harald Wajant
  • Frank Henkler
Part of the Medical Intelligence Unit book series (MIUN)


The physiological roles of the FasL-Fas system include apoptosis-related processes like tumor surveillance, elimination of virus infected cells or deletion of autoreactive T- and B-cells. In recent years there is also emerging evidence for nonapoptotic functions of these molecules in liver regeneration, T-cell activation and neurite differentiation. Disregulation or malfunction of FasL or Fas have been implicated in a variety of pathological situations including autoimmune diseases, fulminant hepatitis, graft versus host disease and spinal cord injury. This chapter is focused on current concepts of either inhibition or activation of Fas signaling as a therapeutic mean. Especially strategies that avoid the severe side effects of systemic Fas activation are discussed.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cohen PL, Eisenberg RA. Lpr and gld: Single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991; 9:243–269.PubMedCrossRefGoogle Scholar
  2. 2.
    Dhein J, Walczak H, Baumler C et al. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995; 373:438–441.PubMedCrossRefGoogle Scholar
  3. 3.
    Brunner T, Mogil RJ, LaFace D et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 1995; 373:441–444.PubMedCrossRefGoogle Scholar
  4. 4.
    Ju ST, Panka DJ, Cui H et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995; 373:444–448.PubMedCrossRefGoogle Scholar
  5. 5.
    Bonfoco E, Stuart PM, Brunner T et al. Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells. Immunity 1998; 9:711–720.PubMedCrossRefGoogle Scholar
  6. 6.
    Mogil RJ, Radvanyi L, Gonzalez-Quintial R et al. Fas (CD95) participates in peripheral T cell deletion and associated apoptosis in vivo. Int Immunol 1995; 7:1451–1458.PubMedCrossRefGoogle Scholar
  7. 7.
    Singer GG, Abbas AK. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1994; 1:365–371.PubMedCrossRefGoogle Scholar
  8. 8.
    Sytwu HK, Liblau RS, McDevitt HO. The roles of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice. Immunity 1996; 5:17–30.PubMedCrossRefGoogle Scholar
  9. 9.
    Pinkoski MJ, Droin NM, Lin T et al. Nonlymphoid Fas ligand in peptide-induced peripheral lymphocyte deletion. Proc Natl Acad Sci USA 2002; 99:16174–16179.PubMedCrossRefGoogle Scholar
  10. 10.
    Mixter PF, Russell JQ, Durie FH et al. Decreased CD4-CD8-TCR-alpha beta + cells in lpr/lpr mice lacking beta 2-microglobulin. J Immunol 1995; 154:2063–2074.PubMedGoogle Scholar
  11. 11.
    Ohteki T, Iwamoto M, Izui S et al. Reduced development of CD4-8-B220+ T cells but normal autoantibody production in lpr/lpr mice lacking major histocompatibility complex class I molecules. Eur J Immunol 1995; 25:37–41.PubMedCrossRefGoogle Scholar
  12. 12.
    Merino R, Fossati L, Iwamoto M et al. Effect of long-term anti-CD4 or anti-CD8 treatment on the development of lpr CD4-CD8-double negative T cells and of the autoimmune syndrome in MRL-lpr/lpr mice. J Autoimmun 1995; 8:33–45.PubMedCrossRefGoogle Scholar
  13. 13.
    Pestano GA, Zhou Y, Trimble LA et al. Inactivation of misselected CD8 T cells by CD8 gene methylation and cell death. Science 1999; 284:1187–1191.PubMedCrossRefGoogle Scholar
  14. 14.
    Trimble LA, Prince KA, Pestano GA et al. Fas-dependent elimination of nonselected CD8 cells and lpr disease. J Immunol 2002; 168:4960–4967.PubMedGoogle Scholar
  15. 15.
    Lee HO, Ferguson TA. Biology of FasL. Cytokine Growth Factor Rev 2003; 14:325–335.PubMedCrossRefGoogle Scholar
  16. 16.
    Alderson MR, Armitage RJ, Maraskovsky E et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med 1993; 178:2231–2235.PubMedCrossRefGoogle Scholar
  17. 17.
    Kennedy NJ, Kataoka T, Tschopp J et al. Caspase activation is required for T cell proliferation. J Exp Med 1999; 190:1891–1896.PubMedCrossRefGoogle Scholar
  18. 18.
    Alam A, Cohen LY, Aouad S et al. Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells. J Exp Med 1999; 190:1879–1890.PubMedCrossRefGoogle Scholar
  19. 19.
    Mack A, Hacker G. Inhibition of caspase or FADD function blocks proliferation but not MAP kinase-activation and interleukin-2-production during primary stimulation of T cells. Eur J Immunol 2002; 32:1986–1992.PubMedCrossRefGoogle Scholar
  20. 20.
    Newton K, Harris AW, Bath ML et al. A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. Embo J 1998; 17:706–718.PubMedCrossRefGoogle Scholar
  21. 21.
    Walsh CM, Wen BG, Chinnaiyan AM et al. A role for FADD in T cell activation and development. Immunity 1998; 8:439–449.PubMedCrossRefGoogle Scholar
  22. 22.
    Zhang J, Cado D, Chen A et al. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mortl. Nature 1998; 392:296–300.PubMedCrossRefGoogle Scholar
  23. 23.
    Chun HJ, Zheng L, Ahmad M et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 2002; 419:395–399.PubMedCrossRefGoogle Scholar
  24. 24.
    Green DR, Ferguson TA. The role of Fas ligand in immune privilege. Nat Rev Mol Cell Biol 2001; 2:917–924.PubMedCrossRefGoogle Scholar
  25. 25.
    Griffith TS, Brunner T, Fletcher SM et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270:1189–1192.PubMedCrossRefGoogle Scholar
  26. 26.
    Stuart PM, Griffith TS, Usui N et al. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest 1997; 99:396–402.PubMedGoogle Scholar
  27. 27.
    Griffith TS, Yu X, Herndon JM et al. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 1996; 5:7–16.PubMedCrossRefGoogle Scholar
  28. 28.
    Hu MS, Schwartzman JD, Yeaman GR et al. Fas-FasL interaction involved in pathogenesis of ocular toxoplasmosis in mice. Infect Immun 1999; 67:928–935.PubMedGoogle Scholar
  29. 29.
    Yamagami S, Kawashima H, Tsuru T et al. Role of Fas-Fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants. Transplantation 1997; 64:1107–1111.PubMedCrossRefGoogle Scholar
  30. 30.
    Villunger A, Egle A, Marschitz I et al. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor-induced suppression of immune surveillance. Blood 1997; 90:12–20.PubMedGoogle Scholar
  31. 31.
    O’Connell J, O’Sullivan GC, Collins JK et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184:1075–1082.PubMedCrossRefGoogle Scholar
  32. 32.
    Hahne M, Rimoldi D, Schroter M et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape. Science 1996; 274:1363–1366.PubMedCrossRefGoogle Scholar
  33. 33.
    Niehans GA, Brunner T, Frizelle SP et al. Human lung carcinomas express Fas ligand. Cancer Res 1997; 57:1007–1012.PubMedGoogle Scholar
  34. 34.
    Strand S, Hofmann WJ, Hug H et al. Lymphocyte apoptosis induced by CD 95 (APO-1/Fas) ligand-expressing tumor cells—a mechanism of immune evasion? Nat Med 1996; 2:1361–1366.PubMedCrossRefGoogle Scholar
  35. 35.
    Bennett MW, O’Connell J, O’Sullivan GC et al. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998; 160:5669–5675.PubMedGoogle Scholar
  36. 36.
    Arai H, Chan SY, Bishop DK et al. Inhibition of the alloantibody response by CD95 ligand. Nat Med 1997; 3:843–848.PubMedCrossRefGoogle Scholar
  37. 37.
    Nishimatsu H, Takeuchi T, Ueki T et al. CD95 ligand expression enhances growth of murine renal cell carcinoma in vivo. Cancer Immunol Immunother 1999; 48:56–61.PubMedCrossRefGoogle Scholar
  38. 38.
    Yagita H, Seino K, Kayagaki N et al. CD95L in graft rejection. Nature 1996; 379:682.PubMedCrossRefGoogle Scholar
  39. 39.
    Seino K, Kayagaki N, Okumura K et al. Antitumor effect of locally produced CD95 ligand. Nat Med 1997; 3:165–170.PubMedCrossRefGoogle Scholar
  40. 40.
    Okamoto S, Takamizawa S, Bishop W et al. Overexpression of Fas ligand does not confer immune privilege to a pancreatic beta tumor cell line (betaTC-3). J Surg Res 1999; 84:77–81.PubMedCrossRefGoogle Scholar
  41. 41.
    Shimizu M, Fontana A, Takeda Y et al. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells. J Immunol 1999; 162:7350–7357.PubMedGoogle Scholar
  42. 42.
    Behrens CK, Igney FH, Arnold B et al. CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice. J Immunol 2001; 166:3240–3247.PubMedGoogle Scholar
  43. 43.
    Simon AK, Gallimore A, Jones E et al. Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies. Cancer Cell 2002; 2:315–322.PubMedCrossRefGoogle Scholar
  44. 44.
    Seino K, Iwabuchi K, Kayagaki N et al. Chemotactic activity of soluble Fas ligand against phagocytes. J Immunol 1998; 161:4484–4488.PubMedGoogle Scholar
  45. 45.
    Ottonello L, Tortolina G, Amelotti M et al. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J Immunol 1999; 162:3601–3606.PubMedGoogle Scholar
  46. 46.
    Shudo K, Kinoshita K, Imamura R et al. The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity. Eur J Immunol 2001; 31:2504–2511.PubMedCrossRefGoogle Scholar
  47. 47.
    Hohlbaum AM, Moe S, Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med 2000; 191:1209–1220.PubMedCrossRefGoogle Scholar
  48. 48.
    Kang SM, Braat D, Schneider DB et al. A noncleavable mutant of Fas ligand does not prevent neutrophilic destruction of islet transplants. Transplantation 2000; 69:1813–1817.PubMedCrossRefGoogle Scholar
  49. 49.
    Miwa K, Asano M, Horai R et al. Caspase 1-independent IL-lbeta release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 1998; 4:1287–1292.PubMedCrossRefGoogle Scholar
  50. 50.
    Rescigno M, Piguet V, Valzasina B et al. Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: A new role for Fas ligand in inflammatory responses. J Exp Med 2000; 192:1661–1668.PubMedCrossRefGoogle Scholar
  51. 51.
    Tada Y, OW J, Takiguchi Y et al. Cutting edge: A novel role for Fas ligand in facilitating antigen acquisition by dendritic cells. J Immunol 2002; 169:2241–2245.PubMedGoogle Scholar
  52. 52.
    Guo Z, Zhang M, An H et al. Fas ligation induces IL-1beta-dependent maturation and IL-1beta-independent survival of dendritic cells: Different roles of ERK and NF-kappaB signaling pathways. Blood 2003; 102:4441–4447.PubMedCrossRefGoogle Scholar
  53. 53.
    Igney FH, Krammer PH. Death and anti-death: Tumour resistance to apoptosis. Nat Rev Cancer 2002; 2:277–288.PubMedCrossRefGoogle Scholar
  54. 54.
    Wajant H, Pfizenmaier K, Scheurich P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis 2002; 7:449–459.PubMedCrossRefGoogle Scholar
  55. 55.
    Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003; 22:8628–8633.PubMedCrossRefGoogle Scholar
  56. 56.
    Davidson WF, Giese T, Fredrickson TN. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J Exp Med 1998; 187:1825–1838.PubMedCrossRefGoogle Scholar
  57. 57.
    Zornig M, Grzeschiczek A, Kowalski MB et al. Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV. Oncogene 1995; 10:2397–2401.PubMedGoogle Scholar
  58. 58.
    Peng SL, Robert ME, Hayday AC et al. A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice. J Exp Med 1996; 184:1149–1154.PubMedCrossRefGoogle Scholar
  59. 59.
    Traver D, Akashi K, Weissman IL et al. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity 1998; 9:47–57.PubMedCrossRefGoogle Scholar
  60. 60.
    Owen-Schaub L, Chan H, Cusack JC et al. Fas and Fas ligand interactions in malignant disease. Int J Oncol 2000; 17:5–12.PubMedGoogle Scholar
  61. 61.
    Owen-Schaub LB, van Golen KL, Hill LL et al. Fas and Fas ligand interactions suppress melanoma lung metastasis. J Exp Med 1998; 188:1717–1723.PubMedCrossRefGoogle Scholar
  62. 62.
    Wigginton JM, Lee JK, Wiltrout TA et al. Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-gamma and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2. J Immunol 2002; 169:4467–4474.PubMedGoogle Scholar
  63. 63.
    Wigginton JM, Gruys E, Geiselhart L et al. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 2001; 108:51–62.PubMedCrossRefGoogle Scholar
  64. 64.
    Choi C, Benveniste EN. Fas ligand/Fas system in the brain: Regulator of immune and apoptotic responses. Brain Res Rev 2004; 44:65–81.PubMedCrossRefGoogle Scholar
  65. 65.
    Shinohara H, Yagita H, Ikawa Y et al. Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation. Cancer Res 2000; 60:1766–1772.PubMedGoogle Scholar
  66. 66.
    Desbarats J, Birge RB, Mimouni-Rongy M et al. Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat Cell Biol 2003; 5:118–125.PubMedCrossRefGoogle Scholar
  67. 67.
    Lambert C, Landau AM, Desbarats J. Fas-beyond death: A regenerative role for Fas in the nervous system. Apoptosis 2003; 8:551–562.PubMedCrossRefGoogle Scholar
  68. 68.
    Ruckenstein MJ, Milburn M, Hu L. Strial dysfunction in the MRL-Fas mouse. Otolaryngol Head Neck Surg 1999; 121:452–456.PubMedCrossRefGoogle Scholar
  69. 69.
    Ruckenstein MJ, Sarwar A, Hu L et al. Marion TN. Effects of immunosuppression on the development of cochlear disease in the MRL-Fas(lpr) mouse. Laryngoscope 1999; 109:626–630.PubMedCrossRefGoogle Scholar
  70. 70.
    Hess DC, Taormina M, Thompson J et al. Cognitive and neurologic deficits in the MRL/lpr mouse: A clinicopathologic study. J Rheumatol 1993; 20:610–617.PubMedGoogle Scholar
  71. 71.
    Moalem G, Leibowitz-Amit R, Yoles E et al. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 1999; 5:49–55.PubMedCrossRefGoogle Scholar
  72. 72.
    Lucas R, Holmgren L, Garcia I et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 1998; 92:4730–4741.PubMedGoogle Scholar
  73. 73.
    Jimenez B, Volpert OV, Crawford SE et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000; 6:41–48.PubMedCrossRefGoogle Scholar
  74. 74.
    Stellmach V, Crawford SE, Zhou W et al. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA 2001; 98:2593–2597.PubMedCrossRefGoogle Scholar
  75. 75.
    Volpert OV, Zaichuk T, Zhou W et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002; 8:349–357.PubMedCrossRefGoogle Scholar
  76. 76.
    Zaichuk TA, Shroff EH, Emmanuel R et al. Nuclear factor of activated T cells balances angiogenesis activation and inhibition. J Exp Med 2004; 199:1513–1522.PubMedCrossRefGoogle Scholar
  77. 77.
    Kamphaus GD, Colorado PC, Panka DJ et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000; 275:1209–1215.PubMedCrossRefGoogle Scholar
  78. 78.
    Panka DJ, Mier JW. Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J Biol Chem 2003; 278:37632–37636.PubMedCrossRefGoogle Scholar
  79. 79.
    Filippatos G, Leche C, Sunga R et al. Expression of FAS adjacent to fibrotic foci in the failing human heart is not associated with increased apoptosis. Am J Physiol 1999; 277:H445–451.PubMedGoogle Scholar
  80. 80.
    Badorff C, Ruetten H, Mueller S et al. Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload. J Clin Invest 2002; 109:373–381.PubMedCrossRefGoogle Scholar
  81. 81.
    Choukroun G, Hajjar R, Fry S et al. Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH(2)-terminal kinases. J Clin Invest 1999; 104:391–398.PubMedGoogle Scholar
  82. 82.
    Esposito G, Prasad SV, Rapacciuolo A et al. Cardiac overexpression of a G(q) inhibitor blocks induction of extracellular signal-regulated kinase and c-Jun NH(2)-terminal kinase activity in vivo pressure overload. Circulation 2001; 103:1453–1458.PubMedGoogle Scholar
  83. 83.
    Watanabe-Fukunaga R, Brannan CI, Copeland NG et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356:314–317.PubMedCrossRefGoogle Scholar
  84. 84.
    Takahashi T, Tanaka M, Brannan CI et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76:969–976.PubMedCrossRefGoogle Scholar
  85. 85.
    Rieux-Laucat F, Fischer A, Deist FL. Cell-death signaling and human disease. Curr Opin Immunol 2003; 15:325–331.PubMedCrossRefGoogle Scholar
  86. 86.
    Siegel RM, Chan FK, Chun HJ et al. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 2000; 1:469–474.PubMedCrossRefGoogle Scholar
  87. 87.
    Sabelko KA, Kelly KA, Nahm MH et al. Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. J Immunol 1997; 159:3096–3099.PubMedGoogle Scholar
  88. 88.
    Waldner H, Sobel RA, Howard E et al. Fas-and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis. J Immunol 1997; 159:3100–3103.PubMedGoogle Scholar
  89. 89.
    Malipiero U, Frei K, Spanaus KS et al. Myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis is chronic/relapsing in perforin knockout mice, but monophasic in Fas-and Fas ligand-deficient lpr and gld mice. Eur J Immunol 1997; 27:3151–3160.PubMedCrossRefGoogle Scholar
  90. 90.
    Sabelko-Downes KA, Cross AH, Russell JH. Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis. J Exp Med 1999; 189:1195–1205.PubMedCrossRefGoogle Scholar
  91. 91.
    Dittel BN, Merchant RM, Janeway Jr CA. Evidence for Fas-dependent and Fas-independent mechanisms in the pathogenesis of experimental autoimmune encephalomyelitis. J Immunol 1999; 162:6392–6400.PubMedGoogle Scholar
  92. 92.
    Okuda Y, Sakoda S, Fujimura H et al. Intrathecal administration of neutralizing antibody against Fas ligand suppresses the progression of experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun 2000; 275:164–168.PubMedCrossRefGoogle Scholar
  93. 93.
    Wildbaum G, Westermann J, Maor G et al. A targeted DNA vaccine encoding fas ligand defines its dual role in the regulation of experimental autoimmune encephalomyelitis. J Clin Invest 2000; 106:671–679.PubMedGoogle Scholar
  94. 94.
    Suvannavejh GC, Dal Canto MC, Matis LA et al. Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis. J Clin Invest 2000; 105:223–231.PubMedGoogle Scholar
  95. 95.
    Galle PR, Hofmann WJ, Walczak H et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995; 182:1223–1230.PubMedCrossRefGoogle Scholar
  96. 96.
    Kondo T, Suda T, Fukuyama H et al. Essential roles of the Fas ligand in the development of hepatitis. Nat Med 1997; 3:409–413.PubMedCrossRefGoogle Scholar
  97. 97.
    Chisari FV. Cytotoxic T cells and viral hepatitis. J Clin Invest 1997; 99:1472–1477.PubMedGoogle Scholar
  98. 98.
    Tsai SL, Huang SN. T cell mechanisms in the immunopathogenesis of viral hepatitis B and C. J Gastroenterol Hepatol 1997; 12:227–235.Google Scholar
  99. 99.
    Hayashi N, Mita E. Fas system and apoptosis in viral hepatitis. J Gastroenterol Hepatol 1997; 12:223–226.Google Scholar
  100. 100.
    Mochizuki K, Hayashi N, Hiramatsu N et al. Fas antigen expression in liver tissues of patients with chronic hepatitis B. J Hepatol 1996; 6:1–7.CrossRefGoogle Scholar
  101. 101.
    Yoo YG, Lee JS, Lee MO. Hepatitis B virus X protein induces expression of fas ligand gene through enhancing transcriptional activity of early growth response factor. J Biol Chem 2004, Epub ahead of print.Google Scholar
  102. 102.
    Lee SH, Shin MS, Lee HS et al. Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Hum Pathol 2001; 32(3):250–256.PubMedCrossRefGoogle Scholar
  103. 103.
    Tsutsui H, Kayagaki N, Kuida K et al. Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity 1999; 11:359–367.PubMedCrossRefGoogle Scholar
  104. 104.
    Seino K, Kayagaki N, Takeda K et al. Contribution of Fas ligand to T cell-mediated hepatic injury in mice. Gastroenterology 1997; 113:1315–1322.PubMedCrossRefGoogle Scholar
  105. 105.
    Tagawa Y, Kakuta S, Iwakura Y. Involvement of Fas/Fas ligand system-mediated apoptosis in the development of concanavalin A-induced hepatitis. Eur J Immunol 1998; 28:4105–4113.PubMedCrossRefGoogle Scholar
  106. 106.
    Adachi M, Suematsu S, Kondo T et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 1995; 11:294–300.PubMedCrossRefGoogle Scholar
  107. 107.
    Desbarats J, Newell MK. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med 2000; 6:920–923.PubMedCrossRefGoogle Scholar
  108. 108.
    Raoul C, Henderson CE, Pettmann B. Programmed cell death of embryonic motoneurons triggered through the Fas death receptor. J Cell Biol 1999; 147:1049–1062.PubMedCrossRefGoogle Scholar
  109. 109.
    Ugolini G, Raoul C, Ferri A et al. Fas/tumor necrosis factor receptor death signaling is required for axotomy-induced death of motoneurons in vivo. J Neurosci 2003; 23:8526–8531.PubMedGoogle Scholar
  110. 110.
    Raoul C, Estevez AG, Nishimune H et al. Motoneuron death triggered by a specific pathway downstream of Fas. potentiation by ALS-linked SOD1 mutations. Neuron 2002; 35:1067–1083.PubMedCrossRefGoogle Scholar
  111. 111.
    Demjen D, Klussmann S, Kleber S et al. Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. Nat Med 2004; 10:389–395.PubMedCrossRefGoogle Scholar
  112. 112.
    Holler N, Kataoka T, Bodmer JL et al. Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors. J Immunol Methods 2000; 237:159–173.PubMedCrossRefGoogle Scholar
  113. 113.
    Hasegawa A, Cheng X, Kajino K et al. Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism. Proc Natl Acad Sci USA 2004; 101:6599–6604.PubMedCrossRefGoogle Scholar
  114. 114.
    Ogasawara J, Watanabe-Fukunaga R, Adachi M et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364:806–809.PubMedCrossRefGoogle Scholar
  115. 115.
    Nishimura Y, Hirabayashi Y, Matsuzaki Y et al. In vivo analysis of Fas antigen-mediated apoptosis: Effects of agonistic anti-mouse Fas mAb on thymus, spleen and liver. Int Immunol 1997; 9:307–316.PubMedCrossRefGoogle Scholar
  116. 116.
    Nishimura-Morita Y, Nose M, Inoue T et al. Amelioration of systemic autoimmune disease by the stimulation of apoptosis-promoting receptor Fas with anti-Fas mAb. Int Immunol 1997; 9:1793–1799.PubMedCrossRefGoogle Scholar
  117. 117.
    Barnhart BC, Alappat EC, Peter ME. The CD95 type I/type II model. Semin Immunol 2003; 15:185–193.PubMedCrossRefGoogle Scholar
  118. 118.
    Ichikawa K, Yoshida-Kato H, Ohtsuki M et al. A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicity. Int Immunol 2000; 12:555–562.PubMedCrossRefGoogle Scholar
  119. 119.
    Lau HT, Yu M, Fontana A et al. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996; 273:109–112.PubMedCrossRefGoogle Scholar
  120. 120.
    Allison J, Georgiou HM, Strasser A et al. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 1997; 94:3943–3947.PubMedCrossRefGoogle Scholar
  121. 121.
    Takeda Y, Gotoh M, Dono K et al. Protection of islet allografts transplanted together with Fas ligand expressing testicular allografts. Diabetologia 1998; 41:315–321.PubMedCrossRefGoogle Scholar
  122. 122.
    Li XC, Li Y, Dodge I et al. Induction of allograft tolerance in the absence of Fas-mediated apoptosis. J Immunol 1999; 163:2500–2507.PubMedGoogle Scholar
  123. 123.
    Turvey SE, Gonzalez-Nicolini V, Kingsley CI et al. Fas ligand-transfected myoblasts and islet cell transplantation. Transplantation 2000; 69:1972–1976.PubMedCrossRefGoogle Scholar
  124. 124.
    Zhang H, Yang Y, Horton JL et al. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. J Clin Invest 1997; 100:1951–1957.PubMedGoogle Scholar
  125. 125.
    Kim SH, Kim S, Oligino TJ et al. Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL. Mol Ther 2002; 6:584–590.PubMedCrossRefGoogle Scholar
  126. 126.
    Guery L, Batteux F, Bessis N et al. Expression of Fas ligand improves the effect of IL-4 in collagen-induced arthritis. Eur J Immunol 2000; 30:308–315.PubMedCrossRefGoogle Scholar
  127. 127.
    Morelli AE, Larregina AT, Smith-Arica J et al. Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity. J Gen Virol 1999; 80 (Pt 3):571–583.PubMedGoogle Scholar
  128. 128.
    Ambar BB, Frei K, Malipiero U et al. Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand. Hum Gene Ther 1999; 10:1641–1648.PubMedCrossRefGoogle Scholar
  129. 129.
    Aoki K, Akyurek LM, San H et al. Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy. Mol Ther 2000; 1:555–565.PubMedCrossRefGoogle Scholar
  130. 130.
    Hyer ML, Voelkel-Johnson C, Rubinchik S et al. Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Mol Ther 2000; 2:348–358.PubMedCrossRefGoogle Scholar
  131. 131.
    Rubinchik S, Ding R, Qiu AJ et al. Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system. Gene Ther 2000; 7:875–885.PubMedCrossRefGoogle Scholar
  132. 132.
    Rubinchik S, Wang D, Yu H et al. A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression. Mol Ther 2001; 4:416–426.PubMedCrossRefGoogle Scholar
  133. 133.
    Friesen C, Herr I, Krammer PH et al. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996; 2:574–577.PubMedCrossRefGoogle Scholar
  134. 134.
    Fulda S, Sieverts H, Friesen C et al. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57:3823–3829.PubMedGoogle Scholar
  135. 135.
    Muller M, Strand S, Hug H et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997; 99:403–413.PubMedGoogle Scholar
  136. 136.
    Trauth BC, Klas C, Peters AM et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245:301–305.PubMedCrossRefGoogle Scholar
  137. 137.
    Shimizu M, Yoshimoto T, Nagata S et al. A trial to kill tumor cells through Fas (CD95)-mediated apoptosis in vivo. Biochem Biophys Res Commun 1996; 228:375–379.PubMedCrossRefGoogle Scholar
  138. 138.
    Schneider P, Holler N, Bodmer JL et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998; 187:1205–1213.PubMedCrossRefGoogle Scholar
  139. 139.
    Samel D, Muller D, Gerspach J et al. Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted Activation. J Biol Chem 2003; 278:32077–32082.PubMedCrossRefGoogle Scholar
  140. 140.
    Wajant H, Moosmayer D, Wuest T et al. Differential activation of TRAIL-R1 and-2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 2001; 20:4101–4106.PubMedCrossRefGoogle Scholar
  141. 141.
    Wuest T, Gerlach E, Banerjee D et al. TNF-Selectokine: A novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor. Oncogene 2002; 21:4257–4265.PubMedCrossRefGoogle Scholar
  142. 142.
    Jung G, Grosse-Hovest L, Krammer PH et al. Target cell-restricted triggering of the CD95 (APO-1/ Fas) death receptor with bispecific antibody fragments. Cancer Res 2001; 61:1846–1848.PubMedGoogle Scholar
  143. 143.
    Hagen TL, Eggermont AM. Tumor vascular therapy with TNF: Critical review on animal models. Methods Mol Med 2004; 98:227–246.PubMedGoogle Scholar
  144. 144.
    Grunhagen DJ, Brunstein F, ten Hagen TL et al. TNF-based isolated limb perfusion: A decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas. Cancer Treat Res 2004; 120:65–79.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2006

Authors and Affiliations

  • Harald Wajant
    • 1
  • Frank Henkler
    • 1
  1. 1.Department of Molecular Internal Medicine, Medical Clinic and Polyclinic IIUniversity of WuerzburgWuerzburgGermany

Personalised recommendations